Strengthening Gavi's replenishment with IFFIm
Strengthening Gavi's replenishment with IFFIm
29 August 2024
Credit: Gavi/2023/Kelvin Juma
Funding IFFIm allows countries to make an immediate, significant impact on Gavi’s mission, while ensuring this innovative finance mechanism continues to benefit Gavi, donors, and partners.
IFFIm is vital for the success of Gavi's 6.0 replenishment, offering flexible, long-term financial solutions that help Gavi meet its ambitious goals.
Gavi has made amazing strides in global health over the past 24 years, but there's still plenty to do. Gavi's new Investment Opportunity (IO), launched in Paris in June 2024, outlines plans to accelerate progress by protecting 500 million children and save over 8 million lives between 2026 and 2030. Gavi vaccinated 1 billion children from 2000 to 2020, and the goal is to protect the next billion in half the time, safeguarding against more diseases than ever before.
To reach this milestone, Gavi needs support from all stakeholders, with donors being asked to contribute at least US$ 9 billion in new funding.
IFFIm's key role in Gavi's replenishment
In support of Gavi's 2026-2030 Investment Opportunity IFFIm launched its Investment Case in June, appealing to donors to renew their support for Gavi through long-term support via IFFIm. Funding IFFIm allows countries to make an immediate, significant impact on Gavi’s mission, while ensuring this innovative finance mechanism continues to benefit Gavi, donors, and partners.
Gavi’s long-term funding strategy calls for a proportion of Gavi’s long-term financing to be predictable and flexible capital. Thus, Gavi aims to mobilise 20% of its overall resources (or US$ 2.4 billion) for the 6.0 period (2026-2030) through IFFIm. This means US$ 1.7 billion in proceeds from new donor grants to IFFIm, forming part of Gavi’s overall request.
IFFIm is vital for the success of Gavi's strategy, offering flexible, long-term financial solutions that help Gavi meet its ambitious goals. By leveraging IFFIm, Gavi and its donors can make a outsized, faster impact, protecting millions of children and saving countless lives in the coming years.
Why donors value IFFIm
Donors are drawn to IFFIm as a way to support Gavi 6.0 because of IFFIm’s unique value in crucial funding areas:
- Immediate and Large-Scale Funding: Gavi can access large-scale funding quickly to introduce and scale up high-impact vaccines, like those for malaria, hexavalent, and HPV.
- Long-Term Commitments with Manufacturers: Gavi can make long-term deals with manufacturers, securing vaccine supplies and lowering prices.
- Enhanced Vaccine Procurement Efficiency: The IFFIm Letter of Credit (LoC) Facility boosts Gavi's efficiency in complex supply and demand scenarios.
- Strengthening Health Systems: Early funding helps countries build and maintain critical health systems and helps prevent outbreaks.
- Flexibility for Emergencies: IFFIm provides flexible and surge funding for unexpected events like outbreaks, emergencies and pandemics.
- Time-Flexible Funding: Funding can be timed to maximise outreach to vulnerable communities.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Lifesaving immunisation: progress made possible by IFFIm
29 August 2024
Strengthening Gavi's replenishment with IFFIm
29 August 2024
IFFIm Board of Directors welcomes three new members
01 July 2024